Beat the market the Zacks way: NVIDIA, Bilibili, Novo Nordisk in a nutshell – Stock Market News

Beat the market the Zacks way: NVIDIA, Bilibili, Novo Nordisk in a nutshell

The three most-watched indexes ended the week higher on Friday, with the tech-heavy Nasdaq posting the fourth consecutive weekly gain. The Nasdaq Composite made sizable gains on a broader tech rally, up 4.3% for the week. The S&P 500 and the Dow Jones Industrial Average rose 2.5% and 1.8% respectively.

Important economic indicators like the PCE inflation index showed a slowdown in demand alongside a cooling in inflation. This gives investors hope that the Fed will take these numbers into account ahead of their February meeting, when it is expected to announce the next interest rate hike. Fourth-quarter GDP also beat expectations, indicating that the Fed may be able to achieve a soft landing for the economy despite its tough policy measures.

Although earnings season remains mixed and earnings forecasts are somewhat discouraging, clear signs are emerging that inflation is down and the economy is still resilient. This has created optimism among market participants over the central bank’s decision to push interest rate hikes up to a possible 25 basis points, as all eyes remain on its meeting. february.

Regardless of market conditions, we at Zacks provide investors with unbiased advice on how to beat the market.

As usual, Zacks Research has guided investors over the past three months with its proven methodologies. Given the uncertainty in the market, you might want to check out our exploits to better prepare for your next action.

Here are some of our main achievements:

Bilibili and Rockwell Medical soar after Zacks ranking upgrade

Shares of Bilibili Inc. BILI has jumped 119.3% since being upgraded to Zacks Rank #2 (Buy) on Nov. 14.

another action, Rockwell Medical, Inc. RMTI, which was also upgraded to Zacks rank No. 2 on Nov. 16, has returned 25.8% since then.

Zacks Rank, our short-term rating system, is centered around earnings estimate revisions. Empirical research shows a strong correlation between trends in earnings estimate revisions and short-term stock price movements.

This stock rating system, which uses four factors tied to earnings estimates to categorize stocks into five groups, ranging from Zacks Rank #1 to Zacks Rank #5 (Strong Sell), has an impressive externally audited track record, with Zacks Rank #1 stocks generating an average annual return of +24.8% since 1988. You can see the full list of today’s Zacks Rank #1 stocks here >>>

View Bilibili’s EPS History and Sales Here>>>

See Rockwell Medical’s EPS History and Sales Here>>>

Image source: Zacks Investment Research

Zacks recommendation upgrade drives Bowman Consulting and Commercial Metals up

Shares of Bowman Consulting Group Ltd. BWM and Metal trading company CMC has jumped 44% and 19.1% since its Zacks recommendation was upgraded to Outperform on Nov. 15 and Nov. 14, respectively.

While the Zacks Ranking is our short-term rating system that is most effective over a 1-3 month holding horizon, the Zacks Recommendation aims to predict performance over the next 6-12 months. However, like the Zacks Ranking, the Zacks Recommendation is based on earnings estimate revision trends.

The Zacks recommendation classifies stocks into three groups: outperforming, neutral and underperforming. While these recommendations are determined quantitatively, our analysts have the option to override them for the 1100+ stocks they track based on their best judgment of factors such as valuation, industry conditions and management effectiveness than the quantitative model.

To access our research reports with Zacks recommendations for the 1100+ stocks we cover, click here>>>

Zacks Focus List NVIDIA Model Portfolio, Block Skyrocket

Shares of NVIDIA Corporation NVDA, which belongs to the Zacks Focus List, has climbed 43.9% over the past 12 weeks. The title was added to the Focus List on May 20, 2019. Another Focus-List holding, Block, Inc. SQ, which was added to the portfolio on March 28, 2017, has returned 39.5% over the past 12 weeks.

The Zacks Focus List is a model portfolio of 50 handpicked stocks that have the right fundamental ingredients to outperform the market over the next 12 months. These 50 stocks are selected from a long list of stocks with the highest Zacks rank.

Since its inception on February 1, 1996, the Focus List portfolio has generated an annualized return of +12.9%.

Unlock all of our powerful research, tools and analytics, including Focus List, Zacks #1 Rank List, Stock Research Reports, Zacks Earnings ESP Filter, Premium Filter and more, as part of Zacks Premium. Get full access now >>

Zacks ECAP Stores Novo Nordisk and Oracle Grow Rapidly

Novo Nordisk A/S NVO, a component of our Earnings Certain Admiral Portfolio (ECAP), has jumped 22.9% over the past 12 weeks. Oracle Corporation ORCL trailed Novo Nordisk with returns of 17.1%.

ECAP is a model portfolio of 30 concentrated, ultra-defensive and long-term Buy and Hold stocks.

With little or no turnover and an annual rebalancing frequency, ECAP seeks to minimize capital losses by holding stocks of companies whose earnings streams have a proven track record of over 20 years of surviving periods. recession with minimal impact on overall earnings growth relative to the broader S&P 500. .

ECAP and many other model portfolios are available as part of Zacks Advisor Tools, a cloud-based solution for accessing Zacks’ award-winning stock, mutual fund, and ETF research. Click here to schedule a demo.

Zacks ECDP Stocks Home Depot, CH Robinson Outperforms Peers

Home Depot, Inc. HD, part of our Earnings Certain Dividend (ECDP) portfolio, has returned 11.5% over the past 12 weeks. Another ECDP stock, CH Robinson Worldwide, Inc. CHRW, climbed 8.9% over the same period. Of course, investors’ inclination towards quality dividend-paying stocks to secure an income stream in an environment of heightened market volatility contributed to this performance.

View The Home Depot’s Dividend History Here>>>

View CH Robinson’s Dividend History Here>>>

With an extremely low beta and a history of minimal earnings variability over the past 20+ years, this 25-stock portfolio helps to significantly mitigate risk. ECDP has consistently outperformed the S&P 500 Dividend Aristocrats ETF NOBL.

Click here to access this portfolio on Zacks Advisor Tools.

Just Released: Zacks Top 10 Stocks for 2023

In addition to the investment ideas discussed above, would you like to know our top 10 picks for 2023?

From its creation in 2012 until November, the Zacks Top 10 Stocks portfolio tripled the market, gaining an impressive +884.5% versus +287.4% for the S&P 500. Our research director has now combed through 4,000 companies covered by the Zacks ranking and selected the top 10 tickers to buy and hold in 2023. Don’t miss your chance to always be among the first to participate in these newly released stocks.

See the new Top 10 stocks >>

Want the latest recommendations from Zacks Investment Research? Today you can download 7 best stocks for the next 30 days. Click to get this free report

Novo Nordisk A/S (NVO): Free Stock Analysis Report

NVIDIA Corporation (NVDA): Free Stock Analysis Report

The Home Depot, Inc. (HD): Free Inventory Analysis Report

CH Robinson Worldwide, Inc. (CHRW): Free Inventory Analysis Report

Oracle Corporation (ORCL): Free Inventory Analysis Report

Commercial Metals Company (CMC): Free Inventory Analysis Report

Rockwell Medical, Inc. (RMTI): Free Stock Analysis Report

Block, Inc. (SQ): Free Stock Analysis Report

ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports

Bilibili Inc. Sponsored ADR (BILI): Free Stock Analysis Report

Bowman Consulting Group Ltd. (BWMN): Free Stock Analysis Report

To read this article on, click here.

Zacks Investment Research

                                                                              <p class="body__disclaimer">The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

[gptBeat the market the Zacks way: NVIDIA, Bilibili, Novo Nordisk in a nutshell


Source link